These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 31822948)

  • 1. Pyoderma gangrenosum induced by lenalidomide in a case of multiple myeloma.
    Meunier M; Larabi A; Schacherer M; Deteix C; Courby S; Cahn JY
    Ann Hematol; 2020 Feb; 99(2):379-380. PubMed ID: 31822948
    [No Abstract]   [Full Text] [Related]  

  • 2. Pyoderma gangrenosum due to lenalidomide use for multiple myeloma.
    Dasanu CA; Bockorny B; Alexandrescu DT
    J Oncol Pharm Pract; 2015 Dec; 21(6):471-3. PubMed ID: 24986794
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intermittent granulocyte colony-stimulating factor for neutropenia management in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone.
    Sun HL; Atenafu EG; Yeboah E; Reece DE; Trudel S; Kukreti V; Masih-Khan E; Winter A; Chen C
    Leuk Lymphoma; 2015 Feb; 56(2):407-14. PubMed ID: 24738975
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lenalidomide: an update on evidence from clinical trials.
    Dimopoulos MA; Terpos E
    Blood Rev; 2010 Nov; 24 Suppl 1():S21-6. PubMed ID: 21126633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New immunomodulatory drugs in myeloma.
    Lacy MQ
    Curr Hematol Malig Rep; 2011 Jun; 6(2):120-5. PubMed ID: 21327565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Immunomodulator drugs for the treatment of multiple myeloma].
    Fernández-Lázaro D; Fernández-Lázaro CI; Caballero García A; Córdova Martínez A
    Rev Med Chil; 2018 Dec; 146(12):1444-1451. PubMed ID: 30848748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lenalidomide in the treatment of multiple myeloma: a review.
    Armoiry X; Aulagner G; Facon T
    J Clin Pharm Ther; 2008 Jun; 33(3):219-26. PubMed ID: 18452408
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful treatment of scleromyxedema with daratumumab, lenalidomide and dexamethasone in a patient with multiple myeloma.
    Bettolini L; Bighetti S; Maione V; Ghini I; Segala D; Calzavara-Pinton P
    Australas J Dermatol; 2024 Jun; 65(4):e104-e107. PubMed ID: 38326991
    [No Abstract]   [Full Text] [Related]  

  • 9. A phase I/II trial of the combination of lenalidomide, thalidomide and dexamethasone in relapsed and/or refractory multiple myeloma.
    Lee HC; Shah JJ; Feng L; Morphey A; Johnson RJ; Wesson ET; Wang ML; Alexanian R; Thomas SK; Orlowski RZ; Weber DM
    Am J Hematol; 2019 Dec; 94(12):E319-E322. PubMed ID: 31489991
    [No Abstract]   [Full Text] [Related]  

  • 10. United Kingdom myeloma forum position statement on the use of lenalidomide in multiple myeloma.
    Davies F; Morris C; Bird J; Cook G; Williams C; Tighe J; Cavenagh J; Behrens J; Schey S; Morgan G;
    Int J Lab Hematol; 2009 Apr; 31(2):119-31. PubMed ID: 19016917
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Second-generation immunomodulatory drugs in leptomeningeal myeloma.
    Bohn JP; Willenbacher W; Peschel I; Oberacher H; Steurer M
    Leuk Lymphoma; 2019 Feb; 60(2):550-552. PubMed ID: 30032690
    [No Abstract]   [Full Text] [Related]  

  • 12. Lenalidomide in multiple myeloma.
    Kim Y; Schmidt-Wolf IG
    Expert Rev Anticancer Ther; 2015 May; 15(5):491-7. PubMed ID: 25843431
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma.
    Dimopoulos MA; Dytfeld D; Grosicki S; Moreau P; Takezako N; Hori M; Leleu X; LeBlanc R; Suzuki K; Raab MS; Richardson PG; Popa McKiver M; Jou YM; Shelat SG; Robbins M; Rafferty B; San-Miguel J
    N Engl J Med; 2018 Nov; 379(19):1811-1822. PubMed ID: 30403938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Treatment of multiple myeloma with elotuzumab plus pomalidomide and dexamethasone].
    Rasche L; Einsele H; Nitschmann S
    Internist (Berl); 2019 Jun; 60(6):658-660. PubMed ID: 30941437
    [No Abstract]   [Full Text] [Related]  

  • 15. Lenalidomide and thalidomide: an evolving paradigm for the management of multiple myeloma.
    Anderson KC; Prince HM
    Semin Hematol; 2005 Oct; 42(4 Suppl 4):S1-2. PubMed ID: 16344096
    [No Abstract]   [Full Text] [Related]  

  • 16. Lenalidomide in the treatment of multiple myeloma.
    Rao KV
    Am J Health Syst Pharm; 2007 Sep; 64(17):1799-807. PubMed ID: 17724360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Should prophylactic granulocyte-colony stimulating factor be used in multiple myeloma patients developing neutropenia under lenalidomide-based therapy?
    Mateos MV; García-Sanz R; Colado E; Olazábal J; San-Miguel J
    Br J Haematol; 2008 Feb; 140(3):324-6. PubMed ID: 18067473
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lenalidomide-induced cytokine release syndrome in a patient with multiple myeloma.
    Nakamura N; Kanemura N; Shibata Y; Matsumoto T; Mabuchi R; Nakamura H; Kitagawa J; Goto N; Hara T; Tsurumi H; Moriwaki H
    Leuk Lymphoma; 2014 Jul; 55(7):1691-3. PubMed ID: 24138307
    [No Abstract]   [Full Text] [Related]  

  • 19. Polymorphisms within beta-catenin encoding gene affect multiple myeloma development and treatment.
    Butrym A; Rybka J; Łacina P; Gębura K; Frontkiewicz D; Bogunia-Kubik K; Mazur G
    Leuk Res; 2015 Dec; 39(12):1462-6. PubMed ID: 26521987
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IgG multiple myeloma presented with ulcerative pyoderma gangrenosum.
    Verrou E; Kartsios C; Banti A; Mihou D; Kaloutsi V; Lazaridou A; Zervas K
    Leuk Lymphoma; 2007 Jul; 48(7):1420-2. PubMed ID: 17613774
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.